Notice of intended sale
Open the filing on sec.gov
Neogen Corporation (NEOG)
Nasdaq: NEOG · In Vitro & In Vivo Diagnostic Substances · Lansing, MI · filing with the SEC since 1995
Grade5.5
◀ Past 6.3● Present 5.8▶ Future 4.3
The companyfiscal 2026, as filed
Revenue$870M-2.7%
Net income-$7.9M+99.3%
Earnings per share$-0.04+99.2%
Operating cash flow$83.2M+43.0%
Cash$186M+43.8%
Debt$794M-9.3%
Shareholders’ equity$2.09B+1.0%
Shares, diluted217.5M+0.3%
Return on equity-0.4%
The recordfrom its filings
Filings in 202675
Newest filingNov 4 · 144
Annual reportJul 30, 2026
Quarterly reportOct 7, 2026
Next report due10-Q by Jan 9
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted66
Filer categoryLarge accelerated filer
Trailing twelve months to Aug 2026Revenue $884MNet income -$56.1MCash from operations $85.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
The company now
Neogen reported revenue of $222.8 million for the three months ended 31 August 2026, up from $209.2 million a year earlier 2.
The quarter still ended in a net loss of $11.9 million, against net income of $36.3 million a year before, when a $76.4 million gain on a business sale lifted the result 2.
The operating loss narrowed to $1.8 million from $16.1 million, as gross margin, the share of revenue left after production costs, rose to 47.4 percent from 45.4 percent 2.
The open question is the planned sale of the Genomics business to Zoetis for $160.0 million, now in a second phase of review by Australian and New Zealand competition regulators 2.
The company says those reviews are currently expected to conclude by the end of December 2026 2.
As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.
Newer filings are on file since this was written; an update is queued.
News
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.